MLNT News and Press, Melinta Therapeutics Inc - Ordinary Shares From 03/14/19

Atossa Genetics (NASDAQ: ATOS ) +223%  on expanded access for Endoxifen. More news on: Atossa Genetics Inc., Hancock Jaffe Laboratories, Inc., Safe-T Group Ltd, Stocks on the move, Read more ...

Melinta Therapeutics, Inc. (MLNT) Q4 2018 Earnings Conference Call March 13, 2019 4:30 PM Company Participants Susan Blum - Vice President, Finance John Johnson - Chief Executive Officer and Director Peter Milligan - Chief Financial Officer Conference Call Participants Lou...

Gainers: MLNT   +18.0% . MDB   +18.0% . DOMO   +12.8% . FLNT   +11.1% . NIHD   +5.3% . More news on: Melinta Therapeutics, Inc., MongoDB, Inc., Domo, Inc., Stocks on the move, Read more ...

The following slide deck was published by Melinta Therapeutics, Inc. in conjunction with their 2018 Q4 earnings Read more ...

Melinta Therapeutics (NASDAQ: MLNT ) Q4 results : More news on: Melinta Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...

Melinta Therapeutics (NASDAQ: MLNT ): Q4 GAAP EPS of -$3.94 beats by $1.16 . More news on: Melinta Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

~ Reports Revenue of $96.4 million, Including Net Product Sales of $46.6 million, for the Full-Year 2018 ~ ~ Net Product Sales of $14.6 million for the Fourth Quarter of 2018, up 32 Percent from Prior Quarter ~ ~ Corporate Milestones Across Commercial Operations, Clinical and Busi...

In October 2018, Paratek Pharmaceuticals ( PRTK ) received FDA approvals for its two main products - SEYSARA and NUZYRA. The company also entered into an exclusive licensing agreement with Almirall ( LBTSF ) for the development and commercialization rights of SEYSARA, which was launched in the...

MORRISTOWN, N.J., March 05, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced it intends to release its fourth quarter an...

Melinta Therapeutics (NASDAQ: MLNT ) announces the closing and receipt of the initial $75M disbursement under the previously announced convertible loan facility from Vatera Healthcare Partners LLC on February 22, 2019. More news on: Melinta Therapeutics, Healthcare stocks news, Stocks on...